Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
99 Leser
Artikel bewerten:
(0)

BioGaia AB: BioGaia signs exclusive distribution agreements for its oral health products in the Czech Republic, the Benelux countries and South Africa

BioGaia signs exclusive distribution agreements for its oral health products in the Czech Republic, the Benelux countries and South Africa 

BioGaia has today signed three different agreements, one with Next Force, giving Next Force exclusive sales rights for BioGaia's oral health products in the Czech Republic, one with Ivodent, giving Ivodent exclusive sales rights in South Africa, and one with Oral Company, giving Oral Company exclusive sales rights in the Netherlands, Belgium and Luxembourg. In all countries, the products will be sold under the BioGaia brand and the launch is planned to take place during 2012.

The company in the Czech Republic, Next Force, is a specialised pharmaceutical company that is part of the Pears Health Cyber group. Pears Health is a leading consulting company focusing on e-marketing in the pharma and healthcare sector, and operates the Czech Republic's largest online pharmacy (www.lekarna.cz (http://www.lekarna.cz)). 

"We are satisfied with the agreement with Next Force. The Czech population has prior experience of probiotics and we look forward to being able to offer the market's first probiotic product for oral health," says Peter Rothschild, President of BioGaia.

Ivodent is a South African pharmaceutical company specialised in OTC products, and has since 1998 very successfully launched several oral health products. BioGaia ProDentis will be marketed to dental professionals.

"Both dentists and patients have long been seeking an alternative to chemical and antibacterial products. BioGaia ProDentis is the world's first clinically documented probiotic for oral health, and we look forward to joining forces with BioGaia," says Gary Hockley, President of Ivodent.

"South Africa is one of our most successful markets. Ivodent is an ideal complement to our existing partnership with Akacia, since the company has good experience of sales and marketing to dental professionals," says Peter Rothschild, President of BioGaia.

Oral Company operates in the Netherlands, Belgium and Luxembourg and is specialised in innovative oral health products for the consumer market. 

"BioGaia ProDentis is currently the world's only clinically documented probiotic for oral health. And since several world-leading researchers that we collaborate with support the product, it was easy to begin working with BioGaia," says Mike Kesseler, dentist and co-owner of Oral Company.

The oral health products contain BioGaia's patented and well studied probiotic Lactobacillus reuteri Prodentis. Today BioGaia's oral health products are sold in 12 countries worldwide.

For additional information please contact 
Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia
2012-05-14 BioGaia initiates investigative study in type 2 diabetics
2012-05-09 Annual General Meeting of BioGaia
2012-05-08 Interim report 1 January-31 March 2012

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 15 May 2012, 02:00 pm CET.

BioGaia press release 15 May 2012 (pdf) (http://hugin.info/86913/R/1612303/513186.pdf)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: BioGaia AB via Thomson Reuters ONE

HUG#1612303
© 2012 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.